Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to have here with me today, Dr. Oliver Sartor, who is a Professor of Medicine AND GU medical oncologist at Tulane, as well as being the medical director of […]
Ashish Kamat: Hello, everybody, and welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from MD Anderson Cancer Center. It’s a pleasure to introduce you all today to Max Kates, who really needs no introduction. Even though he’s been in the field relatively for a short duration of time, he’s made a huge impact […]
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving NUBEQA plus androgen deprivation therapy (ADT) had a statistically significant improvement in its secondary endpoint of overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003)1 Updated results on secondary endpoints also show that NUBEQA delayed the time to pain progression, time to first […]
TMPRSS2 is a host co-receptor for cell entry of SARS-CoV-2. One prior report suggested that use of androgen deprivation therapy (ADT), which downregulates TMPRSS2, may protect men with prostate cancer from infection.
Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.
We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial (n = 886; NCT02684006), which demonstrated significantly prolonged progression-free survival (PFS) with first-line avelumab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).
Due to the complicated histopathological characteristics of renal neoplasms, traditional distinguishing of clear-cell renal-cell carcinoma (ccRCC) by naked eyes of experienced pathologist remains labor-intensive and time-consuming.
Magnetic resonance imaging guidance has been sporadically reported for renal tumor cryoablation (CA); therefore, clinical experience with this modality is still limited.The aim of this study is to retrospectively analyze our 10-year experience with renal tumor CA performed on a 1.
To assess the impact of two cycles of neoadjuvant chemotherapy (NAC) in patients who underwent nephroureterectomy for high-risk cN0M0 upper tract urothelial carcinoma (UTUC), and to evaluate the efficacy of NAC in patients with localized disease (cT2 or lower).
Stereotactic body radiation treatment represents an intriguing therapeutic option for patients with early-stage prostate cancer. In this phase II study, stereotactic body radiation treatment was delivered by volumetric modulated arc therapy with flattening filter free beams and was gated using real-time electromagnetic transponder system to maximize precision of radiotherapy and, potentially, to reduce toxicities.
